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Abstract
Background: Conflicting associations with heroin dependence have been found involving the A1
allele of dopamine D2 receptor gene (DRD2) TaqI A polymorphism.
Methods: We compared two samples of unrelated Spanish individuals, all of European origin: 281
methadone-maintained heroin-dependent patients (207 males and 74 females) who frequently used
non-opioid substances, and 145 control subjects (98 males and 47 females).
Results: The A1-A1 genotype was detected in 7.1% of patients and 1.4% of controls (P = 0.011,
odds ratio = 5.48, 95% CI 1.26–23.78). Although the A1 allele was not associated with heroin
dependence in the entire sample, the frequency of A1 allele was higher in male patients than in male
controls (24.4% vs. 16.3%, P = 0.024, odds ratio = 1.65, 95% CI 1.07–2.57). A logistic regression
analysis showed an interaction between DRD2 alleles and gender (odds ratio = 1.77, 95% CI 1.15–
2.70).
Conclusion: Our results indicate that, in Spanish individuals, genotypes of the DRD2 TaqI A
polymorphism contribute to variations in the risk of heroin dependence, while single alleles
contribute only in males.
Background
A better understanding of the etiology of heroin depend-
ence is crucial for improving the prevention and treatment
of this severe mental disorder. Genes that could be risk
factors for heroin dependence have not been consistently
identified; however, genetic epidemiology studies have
shown that they do have an impact. These studies, with
one exception [1], also suggest that such genetic factors
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are mainly nonspecific, because they also confer vulnera-
bility to other substance use disorders (SUD) [2-4].
The gene coding for the dopamine receptor D2 (DRD2)
could be involved in heroin dependence and other SUD
as a nonspecific genetic factor, because opioids and other
substances of abuse induce some of their rewarding effects
through the mesolimbic dopamine system [5,6]. Preclini-
cal research supports this hypothesis. An absence of opi-
oid-rewarding effects has been reported in mice lacking
DRD2 [7].
The DRD2 TaqI A is a SNP with two variants: A1, the less
frequent allele, and A2. The A1 allele is associated with a
reduction in the density of D2 receptors at the striatum [8-
10], although one study failed to replicate this finding
[11]. The hypofunction of D2 receptors associated with
A1 allele could be a risk factor for SUD [12]. Healthy men
who feel psychostimulant effects to be pleasant have
lower D2 receptor availability than those who feel them to
be unpleasant [13]. This result supports a model that links
the A1 allele with SUD through the following sequence of
facts: low D2 receptor density, moderate substance stimu-
lation of dopamine system, and rewarding feelings after
substance use. The addictive process could get started and
continue more easily in men than in women, because D2
receptor density is lower in healthy men [9,14] as well as
in heroin-dependent men [15].
A series of meta-analyses performed on 55 studies has
shown an association between the DRD2 A1 allele and
SUD in Caucasian and non-Caucasian groups [16]. How-
ever, in the particular case of opioid use disorders, associ-
ations with the A1 allele have been found in some studies
[17,18], but not in others [19,20]. The aim of the present
study was to examine the association of heroin depend-
ence with DRD2 A1 alleles in Spanish subjects of Euro-
pean origin.
Methods
Subjects
All subjects included in this study were unrelated and
their four grandparents were Spanish, of European, non-
Roma origin. Patients were in methadone maintenance
for treating heroin dependence (DSM-IV: 304.02;[21]),
and all of them reported heroin as their primary drug of
choice. Non-opioid substance use was not an exclusion
criterion in the present study for two reasons: first,
because heroin-dependent Spanish patients frequently
report use of alcohol, benzodiazepines, cannabis, and
cocaine as a secondary drug [22]; second, because DRD2
is potentially a nonspecific genetic factor for substance
abuse or dependence. Therefore, the exclusion of heroin-
dependent patients who frequently use non-opioid sub-
stances would have reduced the external validity of our
study, without improving its internal validity. In the
present study, non-opioid substance use was defined as a
regular and/or maladaptive use pattern during a lifelong
cumulative period longer than a year. Control individuals
were blood donors and clinical staff members, who
declared that they did not suffer SUD, with the exception
of nicotine dependence. The present study was approved
by the IRB of Sant Pau Hospital (Barcelona), and written
informed consent was obtained from all participants.
Genotyping
A 10-ml sample of venous blood was drawn from each
participant, and DNA was isolated with a salting-out pro-
cedure [23]. All allele types were determined independ-
ently by two laboratory technicians blind to subject
identity. Genotyping of DRD2 TaqI A polymorphism was
performed by PCR as described in [24]. PCR reactions
contained 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 200 μM
each dNTP, 1.5 mM MgCl2, 0.2 μM of each primer and
1.25 units of Taq Polymerase (Promega) in a 25 μl volume
containing 50 ng sample DNA. The reaction mixture was
denatured 4 min at 94°C, followed by 35 cycles of 94°C
for 30 sec, 58°C for 30 sec, 72°C for 30 sec, and a final
extension of 5 min at 72°C. Subsequently, 10 μl of the
PCR product were digested with 5 units of TaqI restriction
enzyme at 65°C overnight. The resulting products were
analysed by electrophoresis and visualised under ultravio-
let light. The A1-A2 genotype is revealed by three frag-
ments (310-bp, 180-bp and 130-bp), the A2-A2 genotype
by two fragments (180-bp and 130-bp), and the A1/A1
genotype is shown by an uncleaved 310-bp fragment.
Statistical analysis
Hardy-Weinberg (HW) equilibrium was tested for the
DRD2 polymorphism. Genotype distributions and allele
frequencies were compared using χ2-test. Moreover, two
logistic regression analyses were performed in order to
examine possible interactive effects of the DRD2 alleles
and genotypes with gender. All statistical tests were two-
sided, and were considered significant at P < 0.05.
Results
The group of patients comprised 281 methadone-main-
tained heroin-dependent individuals (Table 1). Males
accounted for 73.7% of this sample. The mean (SD) age
of the patients was 36.4 (6.3) years. Most patients
reported intravenous (IV) heroin self-administration and
non-opioid substance use (Table 1). In regard to these var-
iables, patients were comparable by gender with the only
exception of cannabis use: male patients reported regular
and/or maladaptive patterns of cannabis use more fre-
quently than female patients. The control group com-
prised 145 subjects recruited from the general population
(128 blood donors and 17 clinical staff). Males accounted
for 67.6% (n = 98) of this sample. The mean (SD) age ofBehavioral and Brain Functions 2007, 3:25 http://www.behavioralandbrainfunctions.com/content/3/1/25
Page 3 of 6
(page number not for citation purposes)
the control subjects was 35.3 (11.2) years. There were no
statistically significant differences with regard to age or
gender between the patients and the controls.
Allele and genotype frequencies of DRD2 polymorphism
are shown in Tables 2 and 3, respectively. Genotype fre-
quencies were in Hardy-Weinberg equilibrium in the con-
trol group (χ2 = 2.01, df = 1, P = 0.16) but not in the
patient group (χ2 = 5.20, df = 1, P = 0.022), probably
because, as described below, the latter group was enriched
in A1-A1 homozygotes. A1 allele frequencies were not sta-
tistically significantly different between patients and con-
trols (χ2 = 2.18, df = 1, P = 0.140). Both groups differed in
genotype frequency (χ2 = 6.48, df = 2, P = 0.039). Notably,
the A1-A1 genotype was detected in 7.1% of patients and
1.4% of controls (χ2 = 6.43, df = 1, P = 0.011, odds ratio =
5.48 [95% CI 1.26–23.78]).
Allelic and genotypic comparisons between genders
showed significant differences only in patients. In this
group, the frequency of the A1 allele (Table 2) was higher
in males than in females (24.4% vs. 14.9%; χ2 = 5.79, df =
1, P = 0.016). However, differences between male and
female patients regarding genotype distribution (Table 3)
did not reach statistical significance (χ2 = 5.37, df = 2, P =
0.068). DRD2 allele and genotype frequencies, however,
were not significantly different between male and female
controls.
Allelic and genotypic comparisons within gender showed
statistically significant differences only in males (Tables 2
and 3). Unlike the results obtained with the whole sam-
ple, patient and control males differed in the frequency of
the A1 allele (χ2 = 5.08, df = 1, P = 0.024, odds ratio = 1.65
[95% CI 1.07–2.57]). The logistic regression analysis
revealed an interaction between DRD2 alleles and gender
(Table 4), such that the frequency of A1 allele was higher
in patient than control males (Table 2). Similarly to the
results obtained with the whole sample, patient and con-
trol males differed in genotype distribution (χ2 = 8.72, df
= 2, P = 0.013). In this case, the logistic regression analysis
did not reveal an interactive effect of DRD2 genotypes and
sex (data not shown).
Discussion
The present case-control study shows that DRD2 contrib-
utes to the variation in the risk for heroin dependence in
Spanish individuals. The A1-A1 genotype was signifi-
cantly associated with heroin dependence in the entire
sample, while the A1 allele was associated only in males.
Accordingly, the conclusion of a series of meta-analyses is
that DRD2 TaqI A polymorphism is associated with SUD,
particularly with severe SUD [16]. We consider that the
patients in the present study suffered a severe SUD,
because they had a long history (≈10 years) of mostly IV
heroin use, which was frequently combined with non-
opioid substance use.
Regarding specific studies on opioid use disorders, our
findings agree with two previous reports from Australia
[17] and Iran [18], and disagree with two other reports
from China [19,20] and Germany [20]. In the Australian
study, patients were in methadone treatment and often
used non-opioid substances, as in the present study. Both
features could maximise a study's ability to detect genetic
associations: with non-opioid substance use, because it is
also related with the DRD2 A1 allele [16]; and with meth-
adone treatment, because it can be a marker of heroin
dependence severity [25].
Table 1: Features of heroin-dependent patientsa
All Males Females Gender comparisons
(n = 281) (n = 207) (n = 74) t or χ2 P
Age (years) 36.4 ± 6.3 36.6 ± 6.2 35.8 ± 6.5 t = 0.92 0.36
Heroin use
Age of onset (years) 20.1 ± 5.3 20.0 ± 5.1 20.3 ± 5.8 t = -0.45 0.66
Route of administration (%)
Intravenous 70.4 73.5 62.5 χ2 = 2.38 0.31
Smoked 10.8 9.5 14.3
Intranasal 18.7 17.0 23.2
Non-opioid substance useb (%)
Alcohol 56.6 59.9 47.3 χ2 = 3.53 0.06
Benzodiazepines 42.7 43.0 41.9 χ2 = 0.03 0.87
Cannabis 81.5 85.0 71.6 χ2 = 6.49 0.01
Cocaine 71.5 70.5 74.3 χ2 = 0.39 0.54
a Values are mean ± SD unless otherwise indicated
b Non-opioid substance use is defined as a regular and/or maladaptative pattern of non-opioid substance use during a longlife cumulative period 
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Patients who participated in the studies showing negative
results [19,20] were not in methadone treatment and, in
the case of the Chinese individuals, rarely used illicit non-
opioid substances. However, the absence of these two fea-
tures does not explain the results obtained: the reason is
that in China, there was little or no availability of illicit
non-opioid substances in the 1990s, and that in both
China and Germany, accessibility to methadone treat-
ment was low or absent during this period. In any case,
the negative results reported by [19] could also be related
with the low severity of the SUD assessed, because this
research group examined associations with opioid abuse,
rather than opioid dependence, as did the remaining
groups.
In the other previous study in which genetic associations
were detected, all participants were males [18]. As this
study did, we found allelic and genotypic associations in
our male subsample. However, the female participation in
our study was useful because it indicated that the geno-
typic association was not gender related, whereas the
allelic association was indeed male-limited. The latter
association could be related to the finding that nonspe-
cific genetic factors account for much more variance per-
centage of illicit opioid use in males (37%) [4] than in
females (3%)[3].
Moreover, gender comparisons in the present study
showed that cannabis use was more frequent in males
than in female patients, and the same trend was found
regarding alcohol use. These differences suggest that our
decision to include patients who use non-opioid sub-
stances in the study maximised the odds for detecting
genetic associations more in males than in females. How-
ever, associations between the DRD2 A1 allele and canna-
bis use disorders have not been published. Moreover,
nonspecific genetic factors account for a larger fraction of
the variance of cannabis use in females (59%)[3] than in
males (34%) [4]. Male-limited associations of the DRD2
A1 allele with alcohol dependence [26] and tobacco
smoking [27] have been reported previously.
Finally, the present study has the following limitations:
1) The associations found could be related more to the
progression and severity of heroin dependence than vul-
nerability to this disorder [28], because patients had a
long history of heroin use; 2) Type II error is a potential
explanation for our findings, since the differences
detected did not reach the significance threshold (i.e.: P <
0.008) when the Bonferroni correction was applied to the
six genetic comparisons performed (Tables 2 and 3); how-
ever, type II error could occur in any direction (i.e., either
Table 3: Distribution of genotypes of DRD2 TaqI A polymorphism in heroin-dependent patients and control individualsa
Allb Malesc Femalesd
Genotypes Patients Controls Total Patients Controls Total Patients Controls Total
A1-A1 20(0.071) 2(0.014) 22(0.052) 17(0.082) 0 17(0.056) 3(0.041) 2(0.043) 5(0.041)
A1-A2 83(0.295) 47(0.324) 130(0.305) 67(0.324) 32(0.327) 99(0.325) 16(0.216) 15(0.319) 31(0.256)
A2-A2 178(0.633) 96(0.662) 274(0.643) 123(0.594) 66(0.673) 189(0.620) 55(0.743) 30(0.638) 85(0.702)
Total 281 145 426 207 98 305 74 47 121
a Normalised frequencies are given in brackets
b χ2 = 6.48, df = 2, P = 0.039
c χ2 = 8.72, df = 2, P = 0.013
d χ2 = 1.64, df = 2, P = 0.440
Table 2: Distribution of alleles of DRD2 TaqI A polymorphism in heroin-dependent patients and control individualsa
Allb Malesc Femalesd
Alleles Patients Controls Total Patients Controls Total Patients Controls Total
A1 123(0.219) 51(0.176) 174(0.204) 101(0.244) 32(0.163) 133(0.218) 22(0.149) 19(0.202) 41(0.169)
A2 439(0.781) 239(0.824) 678(0.796) 313(0.756) 164(0.837) 477(0.782) 126(0.851) 75(0.798) 201(0.831)
Total 562 290 852 414 196 610 148 94 242
a Normalised frequencies are given in brackets
b χ2 = 2.18, df = 1, P = 0.140
c χ2 = 5.08, df = 1, P = 0.024
d χ2 = 1.17, df = 1, P = 0.280Behavioral and Brain Functions 2007, 3:25 http://www.behavioralandbrainfunctions.com/content/3/1/25
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A1 or A2 could have been associated with heroin use),
while we found that the associated allele was A1, just as in
previous reports; 3) The male-limited association of A1
allele with heroin dependence must be considered as a
preliminary finding, because more males than females
participated in the present study and there is no indica-
tion of gender dimorphism in regard with the TaqI A alle-
les in the literature; 4) The findings of the present study
may not be generalizable, because all study participants
belonged to the same population. Still, Spaniards are
closely related to the other European populations, and
one would not expect to find many differences in the
genetic architecture of susceptibility to heroin use.
Conclusion
To our knowledge, this is the first study performed in
Latin Europe regarding the genetic associations of heroin
dependence. The study was aimed to examine the associ-
ation of heroin dependence with the DRD2 TaqI A poly-
morphism in Spanish subjects of European origin.
According with our results, the A1-A1 genotype of the
DRD2 TaqI A polymorphism is associated with heroin
dependence regardless of gender, while the A1 allele is
associated with heroin dependence only in males. These
results must be considered taking into account two
aspects of the participant selection. First, heroin-depend-
ent patients who participated in the present study were
not excluded if they reported non-opioid substance use.
Second, the most of cases and controls were males.
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